Dr. Russell Richardson, Ph.D.

Claim this profile
Studies Pulmonary Arterial Hypertension
Studies High Blood Pressure
1 reported clinical trial
15 drugs studied

Clinical Trials Russell Richardson, Ph.D. is currently running

Image of trial facility.

Vascular Function in Pulmonary Arterial Hypertension

for undefined

Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions. One primary regulator of vasomotion and thus perfusion to the muscle tissue is the host of chemical factors originating from the vascular endothelium and the muscle tissue, which collectively sets the level of vascular tone. With advancing age and in many disease states, deleterious adaptations in the production and sensitivity of these vasodilator and vasoconstrictor substances may be observed, leading to a reduction in skeletal muscle blood flow and compromised perfusion to the muscle tissue. Adequate perfusion is particularly important during exercise to meet the increased metabolic demand of the exercising tissue, and thus any condition that reduces tissue perfusion may limit the capacity for physical activity. As it is now well established that regular physical activity is a key component in maintaining cardiovascular health with advancing age, there is a clear need for further studies in populations where vascular dysfunction is compromised, with the goal of identifying the mechanisms responsible for the dysfunction and exploring whether these maladaptations may be remediable. Thus, to better understand the etiology of these vascular adaptations in health and disease, the current proposal is designed to study changes in vascular function with advancing age, and also examine peripheral vascular changes in patients suffering from chronic obstructive pulmonary disease (COPD), Sepsis, Pulmonary Hypertension, and cardiovascular disease. While there are clearly a host of vasoactive substances which collectively act to govern vasoconstriction both at rest and during exercise, four specific pathways that may be implicated have been identified in these populations: Angiotensin-II (ANG-II), Endothelin-1 (ET-1), Nitric Oxide (NO), and oxidative stress.
Recruiting2 awards Phase 17 criteria

More about Russell Richardson, Ph.D.

Clinical Trial Related16 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Russell Richardson, Ph.D. has experience with
  • Acetylcholine
  • Angiotensin-II
  • BH4
  • BQ-123
  • Fexofenadine
  • L-NMMA

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Russell Richardson, Ph.D. specialize in?
Russell Richardson, Ph.D. focuses on Pulmonary Arterial Hypertension and High Blood Pressure. In particular, much of their work with Pulmonary Arterial Hypertension has involved treating patients, or patients who are undergoing treatment.
Is Russell Richardson, Ph.D. currently recruiting for clinical trials?
Yes, Russell Richardson, Ph.D. is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Russell Richardson, Ph.D. has studied deeply?
Yes, Russell Richardson, Ph.D. has studied treatments such as Acetylcholine, Angiotensin-II, BH4.
What is the best way to schedule an appointment with Russell Richardson, Ph.D.?
Apply for one of the trials that Russell Richardson, Ph.D. is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.